Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lingzi Su"'
Autor:
Lingzi Su, Zhe Wang, Mengcheng Cai, Qin Wang, Man Wang, Wenxiao Yang, Yabin Gong, Fanfu Fang, Ling Xu
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe incidence of breast cancer remains high and severely affects human health. However, given the heterogeneity of tumor cells, identifying additional characteristics of breast cancer cells is essential for accurate treatment.PurposeThis st
Externí odkaz:
https://doaj.org/article/931cff59e8f0417a99215e745407afe8
Autor:
Ao Qi PhD, Yiyun He MD, Yifeng Gu MD, Congmeng Zhang MMed, Xiong Qin MD, Yichao Wang MD, Yong Yang MD, Jialin Yao MD, Huiling Zhou MD, Wenxiao Yang PhD, Lingzi Su MD, Qin Wang PhD, Jiajun Song MMed, Lijing Jiao PhD, Yabin Gong MD, Jiaqi Li MMed, Ling Xu PhD
Publikováno v:
Integrative Cancer Therapies, Vol 23 (2024)
Objective: To observe the clinical efficacy of Chinese herbal medicine combined with Liuzijue exercise on the physiological symptoms and quality of life (QoL) in postoperative patients with early-stage lung cancer. Methods: One hundred and eighty-thr
Externí odkaz:
https://doaj.org/article/020ef9cd683c44a09d2edbedcca458d1
Autor:
Jialin Yao, Yan Lu, Lijing Jiao, Ling Bi, Wenxiao Yang, Lingzi Su, Jun Shi, Zhe Wang, Yabin Gong, Ling Xu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the prognosis of non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Although third-generation EGFR-TKI osimertinib is demons
Externí odkaz:
https://doaj.org/article/b14967b58f2e437bb2fdbafe0d72e8ee
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100345- (2021)
Synchronous malignant mesothelioma (MM) and lung carcinoma are extremely rare in patients without a history of asbestos exposure and poses tremendous difficulties in clinical management. We report a patient without asbestos exposure diagnosed with MM
Externí odkaz:
https://doaj.org/article/599f2cdd3b5b438cbf8ae6ae3a7a71e3
Autor:
Jialin, Yao, Yan, Lu, Lijing, Jiao, Ling, Bi, Wenxiao, Yang, Lingzi, Su, Jun, Shi, Zhe, Wang, Yabin, Gong, Ling, Xu
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the prognosis of non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Although third-generation EGFR-TKI osimertinib is demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462de763284535ffd463ff99ceaaa53f
https://doi.org/10.21203/rs.3.rs-501000/v2
https://doi.org/10.21203/rs.3.rs-501000/v2
Autor:
Ling Xu, Wenxiao Yang, Yan Lu, Bi Ling, Jun Shi, Lijing Jiao, Zhe Wang, Yabin Gong, Jialin Yao, Lingzi Su
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the prognosis of non-small cell lung cancer (NSCLC) with EGFR sensitizing mutation. Although third-generation EGFR-TKI osimertinib is dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16c4725b929b86100d69936f4910eabe
https://doi.org/10.21203/rs.3.rs-501000/v1
https://doi.org/10.21203/rs.3.rs-501000/v1